U.K. Recommends Other Shots For People Under 30

UK health officials have raised concerns about the AstraZeneca COVID-19 vaccine due to potential links to rare blood clots. Despite these concerns, both UK and EU regulators maintain that the vaccine's benefits outweigh the risks. The European Medicines Agency has reviewed cases and confirmed this stance, noting that no specific risk factors have been identified. The vaccine has been administered to 25 million people in Europe, and the overall assessment remains positive.

What is the main concern raised by UK health officials about the Astra Zeneca vaccine?

• It is too expensive for widespread use.

• It requires special storage conditions.

• It is not effective against COVID-19.

• It may be linked to rare blood clots.

What do UK and EU regulators say about the Astra Zeneca vaccine?

• The risks outweigh the benefits.

• It is only suitable for young adults.

• It should be discontinued immediately.

• The benefits outweigh the risks.

What has not been confirmed as a specific risk factor for clotting disorders?

• Vaccination history

• Age

• Diet

• Exercise

What does the European Medicines Agency say about the Astra Zeneca vaccine?

• It is not recommended for people with allergies.

• It is only effective for a short period.

• Its benefits in preventing COVID-19 outweigh the risks.

• It should be avoided by all age groups.

How many people in Europe have received the Astra Zeneca vaccine according to the report?

• 10 million

• 25 million

• 15 million

• 20 million